Idiopathic pulmonary fibrosis (IPF) and diabetes mellitus do not appear to have a causal association, according to study findings published in Thorax.
Leerink Partners analyst Roanna Ruiz has maintained their bullish stance on UTHR stock, giving a Buy rating on January 8.Stay Ahead of the ...
Biopharma executives were busy Monday, striking high-value deals and providing updates on cancer, obesity and vaccine ...
With idiopathic pulmonary fibrosis, columnist Sam Kirton continues to learn to be prepared for emergencies, such as the Los Angeles fires.
Mediar Therapeutics has entered a global licensing agreement with Eli Lilly and Company to progress the human immunoglobulin ...
Researchers assessed the effect of long-term air pollution exposure on disease severity and progression in patients with idiopathic pulmonary fibrosis.
Research highlights gender-based disparities in lung transplantation, showing women face longer wait times yet achieve better ...
IMVARIA Inc., a health tech company pioneering AI-driven digital biomarker solutions, today announced its second FDA authorization, securing 510 (k) clearance from the U.S. Food and Drug ...
Nuformix plc (LON:NFX – Get Free Report)’s share price traded down 18.5% during trading on Monday . The company traded as low as GBX 0.05 ($0.00) and last traded at GBX 0.05 ($0.00). 45,228,297 shares ...
Weill Cornell Medicine researchers have found that pharmacy benefit managers (PBMs)—organizations that negotiate access to medicines for most patients in the United States—steer patients to use their ...
Eli Lilly (NYSE:LLY) has entered into a licensing agreement with Mediar Therapeutics to advance Mediar's drug MTX-463 into ...